Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Boštjan Šeruga) .

1 - 10 / 35
First pagePrevious page1234Next pageLast page
1.
Paratesticular adenocarcinoma : unusual presentation of metastasis of pancreatic cancer
Janja Ocvirk, Boštjan Šeruga, 2007, short scientific article

Abstract: Background. Metastatic paratesticular adenocarcinoma from the pancreatic cancer is very rare. To our knowledge, there are less than 20 cases published in the literature. Case report. We experienced a case of paratesticular adenocarcinoma from the primary pancreatic cancer. A 42-year-old man was presented with locoregionally advanced carcinoma of the tail of the pancreas with intraoperatively found liver metastases and with a tumour in the right hemi-scrotum. Ultrasound of the scrotum revealed a paratesticular tumour. A fine needle aspiration biopsy (FNAB) confirmed a poorly differentiated adenocarcinoma and it was in concordance with the diagnosis of the primary tumour. The patient started treatment with chemotherapy with gemcitabine. Unfortunately, he progressed one month later and the treatment was discontinued. Conclusions. Outcome in the adenocarcinoma of the pancreas is dismal. The only possible treatment option for metastatic disease is systemic therapy but the results are disappointing, as in the present case.
Published in DiRROS: 19.02.2024; Views: 73; Downloads: 22
.pdf Full text (78,71 KB)

2.
Preoperative concomitant chemoradiotherapy in esophageal cancer
Boštjan Šeruga, Mihael Sok, Janez Eržen, Jože Jerman, Boris Jančar, Branko Zakotnik, 2006, original scientific article

Abstract: Background. Currently primary treatment options for esophageal cancer are surgery only or concomitant chemoradiotherapy (CRT) and the long-term survivalof patients with locally advanced disease is rare. Preoperative concomitant CRT seems to be beneficial, mostly in patients who achieve a complete pathologic response (pCR) after CRT. In this retrospective analysis the efficiency and toxicity of preoperative CRT in patients with locally advanced esophageal cancer was analysed as well as the influence of pCR on thesuraival. Patients and metkods From 1996 to 2002 41 patients with locoregionally confined esophageal cancerwere treated with cisplatin 75 mgžm2 and 5-FU 1000 mgžm2 as 4 day contonuous infusion starting on days 1. and 22. with concorrtitant radiotherapy 4500 cGy, 200-300 cGyžday. Esophagectomy followed 4-5 weeks after radiotherapy. After the surgery patients were followed-up regularly at 3-6 months intervals. Results. The pCR was achieved in 26.8% of patients. The overall median survival time was 18 months for all patients, 21.2 months for patients who achieved pCR and 16 months in those with residual disease (p= 0,79). Postoperative mortality rate was 22%. The median dose intensity for cisplatin was 92% and for 5-FU 71.5 of the planned dose. Disease recurred most often locoregionally (31.7%) and the overall recurrence rate was 43.9. Conclusion. Modern radiation techniques and the adequate dose intensity could further improve the locoregional control. The selection of patients without comorbid conditions and without already present distant metastases is essential for this combined treatment approach.
Published in DiRROS: 15.02.2024; Views: 97; Downloads: 25
.pdf Full text (123,83 KB)

3.
Klinično raziskovanje v onkologiji : učbenik za študente medicine in specializante onkologije
Maja Čemažar, 2024, not set

Keywords: onkologija
Published in DiRROS: 29.01.2024; Views: 147; Downloads: 33
.pdf Full text (1,39 MB)

4.
5.
Prihodnost zdravljenja raka prostate
Boštjan Šeruga, 2023, published scientific conference contribution

Abstract: V zadnjem desetletju je bil dosežen velik napredek v zdravljenju raka prostate. Tudi v naslednjem desetletju si obetamo podoben ali še večji napredek. Veliko obetajo kombinacije zdravil, ki jih danes v praksi že uporabljamo, in nova protirakava zdravila. Pri raku prostate ostaja neizkoriščen potencial imunoterapije, ki jo bo v bodoče potrebno še nadgraditi. Hitrejši napredek v zdravljenju raka prostate bodo omogočili sodobni dizajni kliničnih raziskav.
Keywords: rak prostate, onkološko zdravljenje, sistemsko zdravljenje
Published in DiRROS: 03.02.2023; Views: 373; Downloads: 108
.pdf Full text (132,04 KB)

6.
Napovedna vrednost izraženosti androgenskega receptorja za razsoj v kosti pri trojno negativnem raku dojk
Petra Ilenič, Ajda Herman, Erik Langerholc, Barbara Gazić, Boštjan Šeruga, 2022, published professional conference contribution abstract

Keywords: onkologija, rak dojke, kemoterapija
Published in DiRROS: 27.01.2023; Views: 292; Downloads: 86
.pdf Full text (47,32 KB)

7.
8.
Vpliv opustitve dopolnilne kemoterapije na preživetje bolnic z zgodnjim ER+/HER2+ rakom dojk
Valentina Jerič Horvat, Damjan Manevski, Barbara Gazić, Primož Drev, Domen Ribnikar, Erika Matos, Boštjan Šeruga, 2022, published professional conference contribution abstract

Keywords: onkologija, rak dojke, kemoterapija
Published in DiRROS: 27.01.2023; Views: 348; Downloads: 98
.pdf Full text (47,33 KB)

9.
Vrzel v učinkovitosti in toksičnosti v kontroliranih in vsakodnevnih okoliščinah
Boštjan Šeruga, 2022, published scientific conference contribution

Abstract: Randomizirane klinične raziskave (RCT) ter sistematični pregledi in metaanalize, ki temeljijo na RCT, so vir dokazov najvišje kakovosti v medicini. RCT je zunanje veljavna (angl. externally valid), če izsledke iz RCT lahko posplošimo na populacijo bolnikov, ki jo zdravimo v realnem svetu oziroma v vsakodnevnih okoliščinah. Raziskave kažejo, da je preživetje bolnikov z rakom, ki prejemajo sodobna protirakava zdravila v vsakodnevni klinični praksi, pogosto krajše kot preživetje bolnikov, ki so ta ista zdravila prejemali v RCT. Poleg tega je bolnikom v realnem življenjem pogosteje potrebno nižati odmerke zdravil, pogosteje utrpijo resne toksične zaplete in pogosteje so zaradi teh zapletov hospitalizirani kot bolniki v RCT. Populacijske raziskave temeljijo na povezovanju registrov raka z različnimi administrativnimi podatkovnimi bazami. So ključ do kakovostnih podatkov iz vsakodnevnega življenja in so lahko podlaga za izboljšanje zdravstvene oskrbe bolnikov v prihodnosti.
Keywords: neželeni učinki, bolniki, sistemsko zdravljenje
Published in DiRROS: 17.01.2023; Views: 394; Downloads: 89
.pdf Full text (80,30 KB)

10.
Ali je metastatski solidni rak lahko ozdravljiva bolezen
Boštjan Šeruga, 2021, published scientific conference contribution

Keywords: obsevanje, radioterapija, onkološko zdravljenje
Published in DiRROS: 24.03.2022; Views: 434; Downloads: 216
.pdf Full text (325,99 KB)
This document has many files! More...

Search done in 0.27 sec.
Back to top